Cover Page To Our Shareholders Issues and Answers: Contributions That Count Enterprise Profile Financials Summary Financial Review Report of Management Report of Ernst & Young LLP, Independent Auditors Financial Statements Notes to Consolidated Financial Statements Corporate Information Board of Directors and Officers

THE ISSUE "Researchers are challenged to choose the right target to impact the root of disease, not the symptom. With viruses that mutate, a one-step genetic change can render up to $1 billion of drug development useless. Aiming at cellular processes might lead to more effective therapeutics that do not succumb to drug resistance." - Garry P. Nolan, Ph.D. Associate Professor, Microbiology and Immunology, Stanford University School of Medicine; Baxter Laboratory in Genetic Pharmacology OUR EXPERTISE BD Biosciences has in-depth experience in cell biology and related disciplines. Out of that has grown capabilities to isolate, analyze and measure intracellular mechanisms and to understand the interaction of a drug with the complex system within a cell. Among BD Biosciences' principal assets are its human resources-including nearly 200 Ph.D.s, 150 other scientists and more than a dozen M.D.s -and strong technology and intellectual property portfolios. OUR CONTRIBUTION An extensive line of reagents and world-class capabilities in flow cytometry make BD Biosciences a primary resource for researchers pursuing new drugs. To help researchers develop cell-based biological assays for drug screening, BD Biosciences offers an enabling technology- BD Living Colors fluorescent proteins. Additionally, the newly introduced BD FACSAria cell sorter promises some of the most significant advances since BD introduced the first flow cytometers in 1974.

Fluorescent proteins and a new generation of cell sorters aid in drug discovery   The world's population exceeds six billion people-but when it's your health that is in question, it's a population of just one. Helping pharmaceutical and biotechnology companies discover drugs to improve and extend your life is one of BD Biosciences' primary missions.     Fluorescent proteins and cell sorting technology are important tools in drug discovery efforts. BD Living Colors fluorescent proteins-for which BD owns the intellectual property -help researchers understand how proteins interact inside a cell and determine the effects of a potential drug candidate on the cell. Only BD Biosciences offers an entire spectrum of colors, including red, which is offered exclusively by BD Biosciences and offers several advantages over other colors.     Flow cytometers are used to measure fluorescent proteins in biological cells at tremendous speeds and with a high degree of sensitivity. BD Biosciences, the worldwide leader, has introduced a next generation flow cytometer, the BD FACSAria cell sorter system. The new system is a user-friendly flow cytometer designed for the wider scientific community. It is expected to open flow cytometry to more users in many fields of science. At the same time, it delivers greater sensitivity, precision and control along with increased cell analysis and sorting performance.     In another drug discovery initiative, BD Biosciences and NuGenesis Technologies® entered into a strategic alliance to provide a flow cytometry scientific data management solution to help pharmaceutical and biotechnology companies comply with 21 CFR Part 11, an FDA electronic records and signature regulation to aid in the submission and approval of new medicines.